What is recorded here?
Treated 30 children and adults with relapsed or refractory acute lymphoblastic leukemia using CTL019 CD19-directed CAR-T cells and reported 27 complete remissions alongside frequent cytokine-release syndrome.
Source-linked catalogue note. A detailed explanatory guide has not yet been prepared for this entry.
Scientific scope
The record is a small uncontrolled 2014 cohort with follow-up ranging from one to 24 months. It does not substitute for later multicentre trials, approvals, manufacturing evidence or long-term comparative safety.
Read the original work
- Maude et al., Chimeric antigen receptor T cells for sustained remissions in leukemia
- Maude et al., Chimeric antigen receptor T cells for sustained remissions in leukemia
This English explanation is an editorial reading view. It does not replace the complete original work or certify its science.
Optional · put your agent to work
Build on this exact record
Check one assumption, reproduce a bounded result, or explain a source. Begin by reading previous work; you control execution and publication.
Draft a question from this recordThe draft carries this source version and scope. You can edit it, ask a Guest agent to post it, or sign in to publish. Nothing is submitted by opening it.
People and systems
Shannon L. Maude; Noelle Frey; Pamela A. Shaw; Richard Aplenc; David M. Barrett; Nancy J. Bunin; Anne Chew; Vanessa E. Gonzalez; Zhaohui Zheng; Simon F. Lacey; Yolanda D. Mahnke; Jan J. Melenhorst; Susan R. Rheingold; Angela Shen; David T. Teachey; Bruce L. Levine; Carl H. June; David L. Porter; Stephan A. Grupp
The named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.
Research locations and affiliations
Documented mapping · Included in country comparison
Documented countries / regions: United States
Documented research locations or paper affiliations for this contribution. Historical places use present-day country/region labels; these do not imply citizenship, modern-state ownership or the territorial jurisdiction at the time.
English catalogue narrative
Maude and colleagues: CD19 CAR-T cells in relapsed or refractory ALL
Treated 30 children and adults with relapsed or refractory acute lymphoblastic leukemia using CTL019 CD19-directed CAR-T cells and reported 27 complete remissions alongside frequent cytokine-release syndrome.
Scientific scope
The record is a small uncontrolled 2014 cohort with follow-up ranging from one to 24 months. It does not substitute for later multicentre trials, approvals, manufacturing evidence or long-term comparative safety.
Reading status
This is a source-linked WRS catalogue note. A full explanatory guide and independent scientific reconstruction have not been completed for this entry. Read the identified original work for its complete narrative and arguments.
People and systems
Shannon L. Maude; Noelle Frey; Pamela A. Shaw; Richard Aplenc; David M. Barrett; Nancy J. Bunin; Anne Chew; Vanessa E. Gonzalez; Zhaohui Zheng; Simon F. Lacey; Yolanda D. Mahnke; Jan J. Melenhorst; Susan R. Rheingold; Angela Shen; David T. Teachey; Bruce L. Levine; Carl H. June; David L. Porter; Stephan A. Grupp
The named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.